Play Earnings CallPlay Earnings Call
EssilorLuxottica ADR (ESLOY) Q1 2026 Sales/Trading Call April 22, 2026 12:30 PM EDT
Company Participants
Giorgio Iannella – Head of Investor Relations
Stefano Grassi – Chief Financial Officer
Conference Call Participants
Oriana Cardani – Intesa Sanpaolo Equity Research
Hugo Solvet – BNP Paribas, Research Division
Julien Dormois – Jefferies LLC, Research Division
Hassan Al-Wakeel – Barclays Bank PLC, Research Division
Veronika Dubajova – Citigroup Inc., Research Division
Domenico Ghilotti – Equita SIM S.p.A., Research Division
Thierry Cota – BofA Securities, Research Division
Luca Solca – Bernstein Institutional Services LLC, Research Division
Presentation
Giorgio Iannella
Head of Investor Relations
Good morning and good afternoon, everybody. This is Giorgio Iannella from the IR team. Thank you for joining EssilorLuxottica Q1 Revenue Management Call. The group’s CFO, Stefano Grassi, will walk you through the revenue performance of the first quarter of the year. After his presentation, there will be a 30-minute Q&A session. [Operator Instructions] With that, I hand it over to Stefano.
Stefano Grassi
Chief Financial Officer
Hello, everyone, and welcome to our Q1 trading update. We closed 2025 with a double-digit year. The revenue for EssilorLuxottica last year grew 11.2% at constant currency for the full year. And we are now opening up Q1 2026 with another double-digit start.
The first quarter saw revenue up 10.8% at constant currency with a well balanced between professional solution and direct-to-consumer, both of them on a double-digit pace. Our regions show North America up 12.5% at constant currency, while EMEA, Asia Pacific and Latin America, they were all up on the high single digit in Q1.
Our growth profile was very much driven by our traditional business that posted mid-single-digit growth and coupled that on top by a strong demand of AI glasses with a product range to continue to expand sensory introduction of the new Ray-Ban Metaoptics, two models, in particular, Blayzer and
